Halyard Health Upgraded by Zacks to Hold (HYH)

Halyard Health (NYSE:HYH) was upgraded by Zacks from a “sell” rating to a “hold” rating in a report released on Thursday, Market Beat reports.

According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “

A number of other research analysts have also weighed in on HYH. JMP Securities lowered their target price on shares of Halyard Health to $40.00 and set a “market outperform” rating for the company in a report on Wednesday. Deutsche Bank assumed coverage on shares of Halyard Health in a report on Friday, September 11th. They set a “buy” rating and a $40.00 price objective for the company. Raymond James began coverage on shares of Halyard Health in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Finally, Morgan Stanley lowered shares of Halyard Health from an “equal weight” rating to an “underweight” rating and set a $27.00 price objective for the company. in a research report on Monday, October 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Halyard Health presently has a consensus rating of “Hold” and an average price target of $35.67.

In other Halyard Health news, CFO Steven E. Voskuil purchased 1,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was acquired at an average cost of $30.00 per share, for a total transaction of $30,000.00. Following the purchase, the chief financial officer now directly owns 28,729 shares of the company’s stock, valued at approximately $861,870. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert E. Abernathy purchased 10,000 shares of the company’s stock in a transaction on Friday, September 4th. The stock was acquired at an average price of $31.06 per share, with a total value of $310,600.00. Following the completion of the purchase, the chief executive officer now directly owns 80,043 shares in the company, valued at $2,486,135.58. The disclosure for this purchase can be found here.

Shares of Halyard Health (NYSE:HYH) traded up 1.05% during midday trading on Thursday, hitting $30.86. 292,768 shares of the company were exchanged. The firm’s market capitalization is $1.44 billion. Halyard Health has a one year low of $26.58 and a one year high of $50.92. The firm’s 50 day moving average price is $29.41 and its 200 day moving average price is $37.09.

Halyard Health (NYSE:HYH) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The business earned $390 million during the quarter, compared to the consensus estimate of $388 million. The firm’s revenue for the quarter was down 4.5% compared to the same quarter last year. Analysts forecast that Halyard Health will post $2.06 EPS for the current fiscal year.

Halyard Health, Inc. seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company has two business segments: Surgical and Infection Prevention (NYSE:HYH) and Medical Devices. The S&IP business of the Company’s provides healthcare supplies and options that target the prevention of healthcare associated diseases. S&IP’s product portfolio comprises sterilization wrapping, surgical drapes and gowns, facial protection, protective attire and medical exam gloves. Medical Devices section offers a portfolio including postoperative pain management options, minimally invasive interventional (or long-term) pain therapies, closed airway suction systems and enteral feeding tubes, focused on respiratory and digestive health and pain management.

To get a free copy of the research report on Halyard Health (HYH), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Halyard Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Halyard Health and related companies with MarketBeat.com’s FREE daily email newsletter.

<!– –>

Halyard Health Upgraded by Zacks to Hold (HYH)